Abstract Title:

A vanillin derivative suppresses the growth of HT29 cells through the Wnt/β-catenin signaling pathway.

Abstract Source:

Eur J Pharmacol. 2019 Jan 29 ;849:43-49. Epub 2019 Jan 29. PMID: 30707959

Abstract Author(s):

Wantong Ma, Xue Li, Peng Song, Qianqian Zhang, Zhengrong Wu, Jianhui Wang, Xiaofeng Li, Ruixiang Xu, Wenbin Zhao, Yuheng Liu, Huanxiang Liu, Xiaojun Yao, Xiaoliang Tang, Peng Chen

Article Affiliation:

Wantong Ma


Colorectal cancer (CRC) is a common malignancy and the leading cause of cancer death worldwide. According to previous studies, vanillin possesses pharmacological and anticancer activities. In this work, we have modified the structure of vanillin to obtain a vanillin derivative called 4-(1H-imidazo [4,5-f][1,10]-phenanthrolin-2-yl)-2-methoxyphenol (IPM711), which has improved anticancer activity. The present study is intended to explore the anti-colorectal cancer activity of IPM711 in HT29 and HCT116 cells. The results of this study suggest that IPM711 can inhibit the growth, invasion and migration of HT29 and HCT116 cells. Western blot and molecular docking showed that IPM711 could bind to a Wnt/β-catenin signaling receptor to inhibit cell growth, invasion and migration in HT29 cells. Based on these results, IPM711 is a promising anticancer drug candidate for human colorectal cancer therapy.

Print Options

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2022 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.